<DOC>
	<DOCNO>NCT02516033</DOCNO>
	<brief_summary>Recently combine approach surgeon ablation combination endocardial ablation ( hybrid ablation ) introduce . This therapy show excellent result patient previous fail endocardial ablation paroxysmal atrial fibrillation well patient persistent atrial fibrillation . The investigator hypothesize severity atrial remodel patient atrial fibrillation measure clinical factor , echocardiographic parameter , circulate biomarkers genetic background , factor use identify risk profile predict failure hybrid ablation therapy patient atrial fibrillation . Aim study determine risk profile base clinical correlate , circulate biomarkers , genetic background associate failure hybrid ablation procedure , prospective single center registry set . The investigator evaluate consecutive patient agree undergo hybrid ablation procedure atrial fibrillation . The investigator aim total 250 participant . Extra study relate procedure include blood sample biomarkers genetic analysis , prolonged Holter monitoring documentation recurrences atrial fibrillation/atrial flutter/atrial tachycardia , quality life questionnaire . Total follow-up five year . Main study endpoint failure hybrid ablation procedure patient atrial fibrillation , i.e . ( ) symptomatic atrial fibrillation/atrial flutter/atrial tachycardia &gt; 30sec without anti-arrhythmic drug one year follow-up ECG record 3-day Holter monitoring .</brief_summary>
	<brief_title>Hybrid Atrail Fibrillation Ablation Registry</brief_title>
	<detailed_description>Rationale : The investigator hypothesize severity atrial remodel patient atrial fibrillation measure clinical factor , echocardiographic parameter , circulate biomarkers genetic background , factor use identify risk profile predict failure hybrid ablation therapy patient atrial fibrillation . Objective : To determine risk profile base clinical correlate , circulate biomarkers , genetic background associate failure hybrid ablation procedure patient atrial fibrillation . Study design : A prospective single center registry . Study population : Patients agree undergo hybrid ablation procedure atrial fibrillation . The investigator aim total 250 participant . Intervention : Extra study relate procedure include blood sample biomarkers genetic analysis baseline 1 year follow-up ; prolong Holter monitor documentation recurrence atrial fibrillation/ atrial flutter/atrial tachycardia 3 month , 6 month 1 year follow-up ; quality life questionnaire baseline , 1 year 5 year follow-up . Total follow-up duration : Five year . Main study endpoint : Failure hybrid ablation procedure patient atrial fibrillation , i.e . ( ) symptomatic atrial fibrillation/atrial flutter/atrial tachycardia &gt; 30sec without anti-arrhythmic drug one year follow-up ECG record 3-day Holter monitoring .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Patients agree undergo hybrid ablation procedure atrial fibrillation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Hybrid Ablation</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Risk Profile</keyword>
	<keyword>Biomarkers</keyword>
</DOC>